[1]JournaloftheAmericanChemicalSociety,2014,vol.136,#26,p.9308-9319
[1]JournaloftheAmericanChemicalSociety,2014,vol.136,#26,p.9308-9319
[1]JournaloftheAmericanChemicalSociety,2014,vol.136,#26,p.9308-9319
[1]JournaloftheAmericanChemicalSociety,2014,vol.136,#26,p.9308-9319
[1]JournaloftheAmericanChemicalSociety,2014,vol.136,#26,p.9308-9319
[1]JournaloftheAmericanChemicalSociety,2014,vol.136,p.9308-9319
[1]JournaloftheAmericanChemicalSociety,2014,vol.136,p.9308-9319
[1]JournaloftheAmericanChemicalSociety,2014,vol.136,p.9308-9319
[1]JournaloftheAmericanChemicalSociety,2014,vol.136,p.9308-9319
[1]JournaloftheAmericanChemicalSociety,2014,vol.136,p.9308-9319
Title: CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses.
Journal: Proceedings of the National Academy of Sciences of the United States of America 20150825
Title: Bromodomains and their pharmacological inhibitors.
Journal: ChemMedChem 20140301
Title: Hammitzsch A, et al. CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses. Proc Natl Acad Sci U S A. 2015 Aug 25;112(34):10768-73.
Title: Tao J, Inhibition of EP300 and DDR1 synergistically alleviates pulmonary fibrosis in vitro and in vivo. Biomed Pharmacother. 2018 Oct;106:1727-1733.
Title: Hay DA, et al. Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains. J Am Chem Soc. 2014 Jul 2;136(26):9308-19.
